Amerika Serikat - Inggris - NLM (National Library of Medicine)

aurobindo pharma limited - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 10 mg in 5 ml - citalopram oral solution, usp is indicated for the treatment of depression. the efficacy of citalopram oral solution, usp in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram oral solution, usp in hospitalized depressed patients has no

Amerika Serikat - Inggris - NLM (National Library of Medicine)

lannett company, inc. - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 10 mg in 5 ml - citalopram oral solution, usp is indicated for the treatment of depression. the efficacy of citalopram oral solution, usp in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram oral solution, usp in hospitalized depressed patients has not been a

Amerika Serikat - Inggris - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 10 mg in 5 ml - citalopram oral solution is indicated for the treatment of depression. the efficacy of citalopram oral solution in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram oral solution in hospitalized depressed patients has not been adequately studie

Amerika Serikat - Inggris - NLM (National Library of Medicine)

atlantic biologicals corp. - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram oral solution, usp is indicated for the treatment of depression. the efficacy of citalopram oral solution, usp in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram oral solution, usp in hospitalized depressed patients has not bee

Amerika Serikat - Inggris - NLM (National Library of Medicine)

chartwell rx, llc - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram oral solution is indicated for the treatment of depression. the efficacy of citalopram oral solution in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder ( see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram oral solution in hospitalized depressed

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - escitalopram oxalate 12.77mg equivalent to escitalopram 10 mg;   - film coated tablet - 10 mg - active: escitalopram oxalate 12.77mg equivalent to escitalopram 10 mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose macrogol 400 magnesium stearate microcrystalline cellulose purified talc titanium dioxide - in adults: treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - escitalopram oxalate 19.16mg equivalent to escitalopram 15 mg;  ;   - film coated tablet - 15 mg - active: escitalopram oxalate 19.16mg equivalent to escitalopram 15 mg     excipient: colloidal silicon dioxide croscarmellose sodium hypromellose macrogol 400 magnesium stearate microcrystalline cellulose purified talc titanium dioxide

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - escitalopram oxalate 25.54mg equivalent to escitalopram 20 mg;   - film coated tablet - 20 mg - active: escitalopram oxalate 25.54mg equivalent to escitalopram 20 mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose macrogol 400 magnesium stearate microcrystalline cellulose purified talc titanium dioxide - in adults: treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - escitalopram oxalate 6.39mg equivalent to escitalopram 5 mg;  ;   - film coated tablet - 5 mg - active: escitalopram oxalate 6.39mg equivalent to escitalopram 5 mg     excipient: colloidal silicon dioxide croscarmellose sodium hypromellose macrogol 400 magnesium stearate microcrystalline cellulose purified talc titanium dioxide

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - escitalopram - film-coated tablet - 15 milligram(s) - selective serotonin reuptake inhibitors; escitalopram